{"schema_version":"secwatch.filing_event.v1","accession":"0001517022-24-000065","form_type":"8-K","ticker":"AKBA","cik":"0001517022","company_name":"Akebia Therapeutics, Inc.","filed_at":"2024-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.337832+00:00","generated_at":"2026-05-31T10:52:26.375420+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Akebia Q2 2024 net loss narrows to $8.6M; Vafseo launch on track for Jan 2025","bullets":["Total revenues $43.6M (down 23% YoY); Auryxia net product rev $41.2M vs $42.2M in Q2 2023.","Net loss $8.6M vs $11.2M in Q2 2023; cash and equivalents $39.5M as of June 30, 2024.","Vafseo TDAPA application submitted; HCPCS codes expected Oct 2024, TDAPA by Jan 2025.","Set Vafseo WAC at $1,278 for 30-day supply (~$15,500/year); regained full U.S. rights from CSL Vifor.","Auryxia FY 2024 net product revenues expected in line with 2023 level ($167M in 2023)."],"urls":{"canonical":"https://secwatch.observer/filing/0001517022-24-000065","json":"https://secwatch.observer/filing/0001517022-24-000065.json","markdown":"https://secwatch.observer/filing/0001517022-24-000065.md","text":"https://secwatch.observer/filing/0001517022-24-000065.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1517022/000151702224000065/0001517022-24-000065-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1517022/000151702224000065/akba-20240808.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T10:52:26.375420+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}